GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » Cash, Cash Equivalents, Marketable Securities

China Resources Pharmaceutical Group (HKSE:03320) Cash, Cash Equivalents, Marketable Securities : HK$64,824 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities?

China Resources Pharmaceutical Group's quarterly cash, cash equivalents, marketable securities increased from Dec. 2022 (HK$51,952.27 Mil) to Jun. 2023 (HK$61,977.27 Mil) and increased from Jun. 2023 (HK$61,977.27 Mil) to Dec. 2023 (HK$64,824.32 Mil).

China Resources Pharmaceutical Group's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (HK$57,826.40 Mil) to Dec. 2022 (HK$51,952.27 Mil) but then increased from Dec. 2022 (HK$51,952.27 Mil) to Dec. 2023 (HK$64,824.32 Mil).


China Resources Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for China Resources Pharmaceutical Group's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38,912.86 45,800.60 57,826.40 51,952.27 64,824.32

China Resources Pharmaceutical Group Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57,826.40 60,307.57 51,952.27 61,977.27 64,824.32

China Resources Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


China Resources Pharmaceutical Group  (HKSE:03320) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


China Resources Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Pharmaceutical Group (HKSE:03320) Business Description

Traded in Other Exchanges
Address
26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG
CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.
Executives
Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines